<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="52754">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 10, 2017</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02419417</url>
  </required_header>
  <id_info>
    <org_study_id>CA011-001</org_study_id>
    <secondary_id>2015-000324-29</secondary_id>
    <nct_id>NCT02419417</nct_id>
  </id_info>
  <brief_title>Study of BMS-986158 in Subjects With Select Advanced Solid Tumors</brief_title>
  <acronym>BET</acronym>
  <official_title>A Phase I/IIa Trial With BMS-986158, a Small Molecule Inhibitor of the Bromodomain and Extra-Terminal (BET) Proteins, in Subjects With Selected Advanced Solid Tumors</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Bristol-Myers Squibb</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Bristol-Myers Squibb</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to determine the safety, tolerability, pharmacokinetics, and
      pharmacodynamics of BMS-986158 in subjects with select advanced solid tumors.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>June 2015</start_date>
  <completion_date type="Anticipated">December 2018</completion_date>
  <primary_completion_date type="Anticipated">December 2018</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>No masking</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Safety as measured by the rate of adverse events (AEs) and Serious Adverse Events (SAEs)</measure>
    <time_frame>Safety will be evaluated from the time that the subject signs the informed consent, and for 30 days after the last dose of study drug or until AEs have returned to â‰¤ grade 1 or baseline</time_frame>
    <description>Safety as measured by the rate of incidence of adverse events (AEs) at its worst grade, serious adverse events (SAEs) at its worst grade, adverse events leading to discontinuations, deaths, frequency of laboratory test toxicity grade shifting from baseline</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Best Overall Response</measure>
    <time_frame>approximately every 8 weeks until-last dose of BMS-986158, expected average of 4 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Objective Response Rate (ORR)</measure>
    <time_frame>approximately every 8 weeks until-last dose of BMS-986158, expected average of 4 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Duration of Response</measure>
    <time_frame>approximately every 8 weeks until-last dose of BMS-986158, expected average of 4 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Progression Free Survival (PFS)</measure>
    <time_frame>approximately every 8 weeks until-last dose of BMS-986158, expected average of 4 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Progression Free Survival Rate (PFSR) at week 't'</measure>
    <time_frame>approximately every 8 weeks until-last dose of BMS-986158, expected average of 4 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Maximum observed plasma concentration (Cmax) for single dose of BMS-986158</measure>
    <time_frame>Cycle 1 Day 1 to Cycle 8 Day 8 of dosing for 1A , Cycle 1 Day 1 to Cycle 2 Day 8 of dosing for 2A</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time of maximum observed plasma concentration (Tmax) for single dose of BMS-986158</measure>
    <time_frame>Cycle 1 Day 1 to Cycle 8 Day 8 of dosing for 1A , Cycle 1 Day 1 to Cycle 2 Day 8 of dosing for 2A</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Area under the plasma concentration-time curve from time zero to time of last quantifiable concentration (AUC(0-T)) for single dose of BMS-986158</measure>
    <time_frame>Cycle 1 Day 1 to Cycle 8 Day 8 of dosing for 1A , Cycle 1 Day 1 to Cycle 2 Day 8 of dosing for 2A</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Area under the concentration-time curve in one dosing interval (AUC(TAU)) for single dose of BMS-986158</measure>
    <time_frame>Cycle 1 Day 1 to Cycle 8 Day 8 of dosing for 1A , Cycle 1 Day 1 to Cycle 2 Day 8 of dosing for 2A</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Apparent terminal phase half-life (T-HALF) for single dose of BMS-986158</measure>
    <time_frame>Cycle 1 Day 1 to Cycle 8 Day 8 of dosing for 1A , Cycle 1 Day 1 to Cycle 2 Day 8 of dosing for 2A</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Area under the plasma concentration-time curve from time zero extrapolated to infinite time (AUC(INF)) for single dose of BMS-986158</measure>
    <time_frame>Cycle 1 Day 1 to Cycle 8 Day 8 of dosing for 1A , Cycle 1 Day 1 to Cycle 2 Day 8 of dosing for 2A</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Apparent total body clearance, reported only for parent, not for metabolite (CLT/F) for single dose of BMS-986158</measure>
    <time_frame>Cycle 1 Day 1 to Cycle 8 Day 8 of dosing for 1A , Cycle 1 Day 1 to Cycle 2 Day 8 of dosing for 2A</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Apparent volume of distribution of terminal phase, reported only for parent, not for metabolite (Vz/F) for single dose of BMS-986158</measure>
    <time_frame>Cycle 1 Day 1 to Cycle 8 Day 8 of dosing for 1A , Cycle 1 Day 1 to Cycle 2 Day 8 of dosing for 2A</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Maximum observed plasma concentration (Cmax) for multiple dose of BMS-986158</measure>
    <time_frame>Cycle 1 Day 1 to Cycle 8 Day 8 of dosing for 1A , Cycle 1 Day 1 to Cycle 2 Day 8 of dosing for 2A</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time of maximum observed plasma concentration (Tmax) for multiple dose of BMS-986158</measure>
    <time_frame>Cycle 1 Day 1 to Cycle 8 Day 8 of dosing for 1A , Cycle 1 Day 1 to Cycle 2 Day 8 of dosing for 2A</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Area under the plasma concentration-time curve from time zero to time of last quantifiable concentration (AUC(0-T)) for multiple dose of BMS-986158</measure>
    <time_frame>Cycle 1 Day 1 to Cycle 8 Day 8 of dosing for 1A , Cycle 1 Day 1 to Cycle 2 Day 8 of dosing for 2A</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Area under the concentration-time curve in one dosing interval (AUC(TAU)) for multiple dose of BMS-986158</measure>
    <time_frame>Cycle 1 Day 1 to Cycle 8 Day 8 of dosing for 1A , Cycle 1 Day 1 to Cycle 2 Day 8 of dosing for 2A</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The minimum observed concentration within a dosing interval (Cmin) for multiple dose of BMS-986158</measure>
    <time_frame>Cycle 1 Day 1 to Cycle 8 Day 8 of dosing for 1A , Cycle 1 Day 1 to Cycle 2 Day 8 of dosing for 2A</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Concentration at the end of a dosing interval (Ctau) for multiple dose of BMS-986158</measure>
    <time_frame>Cycle 1 Day 1 to Cycle 8 Day 8 of dosing for 1A , Cycle 1 Day 1 to Cycle 2 Day 8 of dosing for 2A</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Trough observed plasma concentration (this includes predose concentrations (C0) and concentrations at the end of dosing interval (Ctau)) (Ctrough) for multiple dose of BMS-986158</measure>
    <time_frame>Cycle 1 Day 1 to Cycle 8 Day 8 of dosing for 1A , Cycle 1 Day 1 to Cycle 2 Day 8 of dosing for 2A</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Degree of Fluctuation or Fluctuation Index ([Cmax-Cmin)/Css-avg]) (DF) for multiple dose of BMS-986158</measure>
    <time_frame>Cycle 1 Day 1 to Cycle 8 Day 8 of dosing for 1A , Cycle 1 Day 1 to Cycle 2 Day 8 of dosing for 2A</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>[Cmax - Cmin] / Cmin; to be calculated at steady-state (Swing) for multiple dose of BMS-986158</measure>
    <time_frame>Cycle 1 Day 1 to Cycle 8 Day 8 of dosing for 1A , Cycle 1 Day 1 to Cycle 2 Day 8 of dosing for 2A</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Accumulation Index (AI) for multiple dose of BMS-986158</measure>
    <time_frame>Cycle 1 Day 1 to Cycle 8 Day 8 of dosing for 1A , Cycle 1 Day 1 to Cycle 2 Day 8 of dosing for 2A</time_frame>
    <description>Ratio of an exposure measure at steady-state to that after the first dose (exposure measure includes AUC(TAU), Cmax and Ctau)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Effective elimination half-life that explains the degree of accumulation observed for a specific exposure measure (T-HALFeff) for multiple dose of BMS-986158</measure>
    <time_frame>Cycle 1 Day 1 to Cycle 8 Day 8 of dosing for 1A , Cycle 1 Day 1 to Cycle 2 Day 8 of dosing for 2A</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Ratio of metabolite Cmax to parent Cmax, corrected for molecular weight (MR_Cmax)</measure>
    <time_frame>Cycle 1 Day 1 to Cycle 8 Day 8 of dosing for 1A , Cycle 1 Day 1 to Cycle 2 Day 8 of dosing for 2A</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Ratio of metabolite AUC(0-T) to parent AUC(0-T), corrected for molecular weight (MR_AUC(0-T))</measure>
    <time_frame>Cycle 1 Day 1 to Cycle 8 Day 8 of dosing for 1A , Cycle 1 Day 1 to Cycle 2 Day 8 of dosing for 2A</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Ratio of metabolite AUC(INF) to parent AUC(INF), corrected for molecular weight (following single dose only) (MR_AUC(INF))</measure>
    <time_frame>Cycle 1 Day 1 to Cycle 8 Day 8 of dosing for 1A , Cycle 1 Day 1 to Cycle 2 Day 8 of dosing for 2A</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Ratio of metabolite AUC(TAU) to parent AUC(TAU), corrected for molecular weight (MR_AUC(TAU))</measure>
    <time_frame>Cycle 1 Day 1 to Cycle 8 Day 8 of dosing for 1A , Cycle 1 Day 1 to Cycle 2 Day 8 of dosing for 2A</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Summary Changes in Expression of BET regulated Genes in Blood</measure>
    <time_frame>Cycle 1 Day 1 through Cycle 2 Day 15 dosing</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes in QTcF</measure>
    <time_frame>Cycle 1 Day 1 to Cycle 8 Day 8 of dosing for 1A , Cycle 1 Day 1 to Cycle 2 Day 8 of dosing for 2A</time_frame>
  </secondary_outcome>
  <number_of_arms>6</number_of_arms>
  <enrollment type="Anticipated">150</enrollment>
  <condition>Multiple Indications Cancer</condition>
  <arm_group>
    <arm_group_label>Part 1 A (Dose Escalation): Treatment Arm A</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Subjects will be treated at increasing doses of BMS-986158 until the maximum tolerated dose is reached.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Part 1A (Dose Escalation): Treatment Arm B</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Subjects will be treated at increasing doses of BMS-986158 until the maximum tolerated dose is reached.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Part 1A (Dose Escalation): Treatment Arm C</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Subjects will be treated at increasing doses of BMS-986158 until the maximum tolerated dose is reached.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Part 2A (Dose Expansion): Treatment Arm A</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Subjects will be treated at maximum tolerated dose.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Part 2A (Dose Expansion): Treatment Arm B</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Subjects will be treated at maximum tolerated dose.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Part 2A (Dose Expansion): Treatment Arm C</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Subjects will be treated at maximum tolerated dose.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>BMS-986158</intervention_name>
    <arm_group_label>Part 1 A (Dose Escalation): Treatment Arm A</arm_group_label>
    <arm_group_label>Part 1A (Dose Escalation): Treatment Arm B</arm_group_label>
    <arm_group_label>Part 1A (Dose Escalation): Treatment Arm C</arm_group_label>
    <arm_group_label>Part 2A (Dose Expansion): Treatment Arm A</arm_group_label>
    <arm_group_label>Part 2A (Dose Expansion): Treatment Arm B</arm_group_label>
    <arm_group_label>Part 2A (Dose Expansion): Treatment Arm C</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        For more information regarding BMS clinical trial participation, please visit
        www.BMSStudyConnect.com

        Inclusion Criteria:

          -  Must have triple negative breast cancer, ovarian (Serous histology for expansion
             phase), small cell lung cancer, or other solid tumors

          -  Expected to have life expectancy of at least 3 months

          -  Men and women 18 years old or older

          -  At least one measurable lesion at baseline by CT or MRI as per response evaluation
             criteria in solid tumors (RECIST) v1.1

          -  Eastern Cooperative Oncology Group (ECOG) of 0 to 1

        Exclusion Criteria:

          -  Serious or uncontrolled medical disorders

          -  Concomitant second malignancies

          -  Uncontrolled or significant cardiovascular disease

          -  Inadequate bone marrow function

        Other protocol defined inclusion/exclusion criteria could apply
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Bristol-Myers Squibb</last_name>
    <role>Study Director</role>
    <affiliation>Bristol-Myers Squibb</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Recruiting sites have contact information. Please contact the sites directly. If there is no contact information, please email:</last_name>
    <email>Clinical.Trials@bms.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>First line of the email MUST contain NCT# and Site #.</last_name>
  </overall_contact_backup>
  <location>
    <facility>
      <name>City Of Hope National Medical Center</name>
      <address>
        <city>Duarte</city>
        <state>California</state>
        <zip>91010</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Mihaela Cristea, Site 0004</last_name>
      <phone>626-359-8111</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>University Of Colorado</name>
      <address>
        <city>Aurora</city>
        <state>Colorado</state>
        <zip>80045</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jennifer Diamond, Site 0020</last_name>
      <phone>720-848-0643</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Portland</city>
        <state>Oregon</state>
        <zip>97239</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Site 0023</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Institute For Translational Oncology Research-Itor</name>
      <address>
        <city>Greenville</city>
        <state>South Carolina</state>
        <zip>29605</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>William Edenfield, Site 0001</last_name>
      <phone>864-679-3926</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Melbourne</city>
        <state>Victoria</state>
        <zip>3004</zip>
        <country>Australia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Site 0006</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Brussels</city>
        <zip>1000</zip>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Site 0008</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Gent</city>
        <zip>9000</zip>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Site 0007</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Ottawa</city>
        <state>Ontario</state>
        <zip>K1H 8L6</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Site 0003</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Toronto</city>
        <state>Ontario</state>
        <zip>M5G 1X6</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Site 0022</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Villejuif</city>
        <zip>94800</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Site 0024</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Maastrict</city>
        <zip>6229 HX</zip>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Site 0011</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Rotterdam</city>
        <zip>3015 CE</zip>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Site 0010</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Madrid</city>
        <zip>28050</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Site 0019</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Pamplona</city>
        <zip>31008</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Site 0018</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>London</city>
        <state>Greater London</state>
        <zip>EC1M 6BQ</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Site 0021</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>London</city>
        <state>Greater London</state>
        <zip>NW1 2PG</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Site 0013</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Manchester</city>
        <state>Greater Manchester</state>
        <zip>M20 4BX</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Site 0014</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Newcastle Upon Tyne</city>
        <zip>NE7 7DN</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Site 0015</last_name>
    </contact>
  </location>
  <location_countries>
    <country>Australia</country>
    <country>Belgium</country>
    <country>Canada</country>
    <country>France</country>
    <country>Netherlands</country>
    <country>Spain</country>
    <country>United Kingdom</country>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://ctr.bms.com/ctd/start.do</url>
    <description>BMS Clinical Trial Information</description>
  </link>
  <link>
    <url>http://www.bms.com/studyconnect/Pages/home.aspx</url>
    <description>BMS clinical trial educational resource</description>
  </link>
  <link>
    <url>http://www.bms.com/clinical_trials/Pages/Investigator_Inquiry_form.aspx</url>
    <description>Investigator Inquiry form</description>
  </link>
  <link>
    <url>http://www.fda.gov/MEDWATCH/safety.htm</url>
    <description>FDA Safety Alerts and Recalls</description>
  </link>
  <verification_date>March 2017</verification_date>
  <lastchanged_date>March 29, 2017</lastchanged_date>
  <firstreceived_date>April 2, 2015</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
